Skip to content

Study · Non-randomized trial · n = 12 · 2003

6 results

The effect of treatment with the oral growth hormone (GH) secretagogue MK-677 on GH isoforms.

Svensson J, Boguszewski CL, Shibata F, Carlsson B, Carlsson LM, Bengtsson BA

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society1 Feb 2003Cited by 3 (Europe PMC)

PMID12550076 (opens in a new tab)DOI10.1016/s1096-6374(02)00138-7 (opens in a new tab)PepBankPUB-12550076
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In obese males, peak non-22K GH proportion after initial MK‑677 administration was higher than after 2 weeks.

    In plain wordsIn obese males, peak non-22K GH proportion was higher after initial MK‑677 administration than after 2 weeks.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreasePeak non-22K GH proportion versus week 2
    Study

    n = 12

    Comparator
    After 2 weeks
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    25mg daily · oral · 8 weeksAs given in this study (human).

    Measurements

    P value for peak non-22K GH proportion
    < 0.01
    Initial MK-677 administration versus week 2; peak total GH samples

    Source sentences

    Summary
    The proportion of non-22K GH isoforms in peak total GH samples after the initial MK-677 administration was higher than that after 2 and 8 weeks (p<0.01 and p<0.05, respectively).
    1 context sentence
    Summary · context
    We have studied the proportion, expressed as percentage of total GH concentration, of non-22kDa (non-22K) GH isoforms and 20K GH during 8-week oral treatment with MK-677 25mg daily in 12 obese males.
  2. 02HumanNon-randomized trialEfficacy outcome

    In obese males, peak non-22K GH proportion after initial MK‑677 administration was higher than after 8 weeks.

    In plain wordsIn obese males, peak non-22K GH proportion was higher after initial MK‑677 administration than after 8 weeks.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreasePeak non-22K GH proportion versus week 8
    Study

    n = 12

    Comparator
    After 8 weeks
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    25mg daily · oral · 8 weeksAs given in this study (human).

    Measurements

    P value for peak non-22K GH proportion
    < 0.05
    Initial MK-677 administration versus week 8; peak total GH samples

    Source sentences

    Summary
    The proportion of non-22K GH isoforms in peak total GH samples after the initial MK-677 administration was higher than that after 2 and 8 weeks (p<0.01 and p<0.05, respectively).
    1 context sentence
    Summary · context
    We have studied the proportion, expressed as percentage of total GH concentration, of non-22kDa (non-22K) GH isoforms and 20K GH during 8-week oral treatment with MK-677 25mg daily in 12 obese males.
  3. 03HumanNon-randomized trialEfficacy outcome

    In obese males, 20K GH proportion in 2-h samples after initial MK‑677 administration was lower than after 2 weeks.

    In plain wordsIn obese males, 20K GH proportion after initial MK‑677 administration was lower than after 2 weeks.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    Decrease20K GH proportion versus week 2
    Study

    n = 12

    Comparator
    After 2 weeks
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    25mg daily · oral · 8 weeksAs given in this study (human).

    Measurements

    P value for 20K GH proportion
    < 0.01
    Initial MK-677 administration versus week 2; 2-h samples

    Source sentences

    Summary
    The proportion of 20K GH in 2-h samples after the initial MK-677 administration was lower than that after 2 and 8 weeks (p<0.01 and p<0.05, respectively).
    1 context sentence
    Summary · context
    We have studied the proportion, expressed as percentage of total GH concentration, of non-22kDa (non-22K) GH isoforms and 20K GH during 8-week oral treatment with MK-677 25mg daily in 12 obese males.
  4. 04HumanNon-randomized trialEfficacy outcome

    In obese males, 20K GH proportion in 2-h samples after initial MK‑677 administration was lower than after 8 weeks.

    In plain wordsIn obese males, 20K GH proportion after initial MK‑677 administration was lower than after 8 weeks.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    Decrease20K GH proportion versus week 8
    Study

    n = 12

    Comparator
    After 8 weeks
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    25mg daily · oral · 8 weeksAs given in this study (human).

    Measurements

    P value for 20K GH proportion
    < 0.05
    Initial MK-677 administration versus week 8; 2-h samples

    Source sentences

    Summary
    The proportion of 20K GH in 2-h samples after the initial MK-677 administration was lower than that after 2 and 8 weeks (p<0.01 and p<0.05, respectively).
    1 context sentence
    Summary · context
    We have studied the proportion, expressed as percentage of total GH concentration, of non-22kDa (non-22K) GH isoforms and 20K GH during 8-week oral treatment with MK-677 25mg daily in 12 obese males.
  5. 05HumanNon-randomized trialEfficacy outcome

    In obese males, the proportion of non-22K GH isoforms in selected non-peak samples after the initial MK‑677 administration was similar to that in peak samples after 2 weeks.

    In plain wordsIn obese males, non-22K GH shares in selected non-peak samples after the first MK‑677 dose resembled peak-sample shares after 2 weeks.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeNon-peak non-22K GH proportion versus week 2
    Study

    n: not reported in source

    Comparator
    Peak samples after 2 weeks
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    25mg daily · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    In selected non-peak total GH samples after the initial MK-677 administration, however, the proportion of non-22K GH isoforms was similar to that in the peak total GH samples after 2 and 8 weeks.
    1 context sentence
    Summary · context
    We have studied the proportion, expressed as percentage of total GH concentration, of non-22kDa (non-22K) GH isoforms and 20K GH during 8-week oral treatment with MK-677 25mg daily in 12 obese males.
  6. 06HumanNon-randomized trialEfficacy outcome

    In obese males, the proportion of non-22K GH isoforms in selected non-peak samples after the initial MK‑677 administration was similar to that in peak samples after 8 weeks.

    In plain wordsIn obese males, non-22K GH shares in selected non-peak samples after the first MK‑677 dose resembled peak-sample shares after 8 weeks.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeNon-peak non-22K GH proportion versus week 8
    Study

    n: not reported in source

    Comparator
    Peak samples after 8 weeks
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    25mg daily · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    In selected non-peak total GH samples after the initial MK-677 administration, however, the proportion of non-22K GH isoforms was similar to that in the peak total GH samples after 2 and 8 weeks.
    1 context sentence
    Summary · context
    We have studied the proportion, expressed as percentage of total GH concentration, of non-22kDa (non-22K) GH isoforms and 20K GH during 8-week oral treatment with MK-677 25mg daily in 12 obese males.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.